Month: June 2021

Advanced Battery Storage Goals of the US Department of Energy

Posted on by Admin 

Image Credit: Charles & Hudson (Flickr)


The U.S. has Solidified its Support for Battery Technology Through 2030

 

The global lithium-based battery market is expected to grow by a factor of 5 to 10 over the next decade. The electric vehicle market often steals the headlines related to the needs of electric power storage systems, but lithium-based batteries are becoming increasingly important for commercial markets, stationary grid-storage systems, national defense, and aviation. Because of the increasing demand for power storage, particularly as it relates to global competition, the U.S. Department of Energy commissioned the Federal Consortium for Advanced Batteries to develop the National Blueprint for Lithium Batteries. The “blueprint” was released this month by the Secretary of Energy. It’s a 24-page document that contains five critical goals to guide collaboration between federal agencies through 2030. Understanding what’s guiding government resources and decisions can benefit investors that seek to benefit from the growth.

 

The 24-page report contains five main goals to achieve the overall vision. Below are the goals further defined by other information pulled from the report. (At the bottom of this article is a link for the full version of The
National Blueprint for Lithium Batteries 2021-2030).

  • Secure access to raw and refined materials and discover alternatives for critical minerals for
    commercial and defense applications.     This goal is set to reduce or eliminate U.S. lithium battery manufacturing dependence on scarce materials such as cobalt and nickel. Securing reliable domestic and foreign sources for critical minerals is a first step toward ultimately replacing the materials in the manufacture of lithium batteries.
  • Support the growth of a U.S. materials-processing base able to meet domestic battery
    manufacturing demand.     At present the US relies on international markets for the processing of most lithium-battery raw materials. The report recommends government involvement in creating greater processing ability within our borders.
  • Stimulate the U.S. electrode, cell, and pack manufacturing sectors. It’s expected that domestic growth and onshoring of cell and pack manufacturing will need ongoing incentives and support for further consumer adoption of EVs. This goal urges developing a federal policy framework that supports manufacturing electrodes, cells, and packs within our borders and encourages incentives to propel demand for lithium-ion batteries.
  • Enable U.S. end-of-life reuse and critical materials recycling at scale and a full
    competitive value chain in the United States.     Recycling lithium-ion cells will help achieve maximize benefit of scarce materials while reducing harmful environmental impacts of mining or disposal. Currently, recyclers face a net end-of-life cost when recycling EV batteries. New more cost efficient methods of testing, transporting, recycling, will be required.
  • Maintain and advance U.S. battery technology leadership by strongly supporting scientific
    R&D, STEM education, and workforce development.     Integral to achieving US leadership is a strong pipeline of R&D, ranging from new electrode and electrolyte materials for next generation lithium-ion batteries, to advances in solid-state batteries, and novel material, electrode, and cell manufacturing methods. The R&D is to be supported by strong intellectual property (IP) protection and rapid movement of innovations from lab to market through public-private R&D partnerships.  

 

Take-Away

The US Department of Energy and the Federal Consortium for the Advancement of Batteries encourage cooperation and coordination across the US Government agencies’ advanced battery efforts to achieve a strong and clean manufacturing and development base. Investors looking to benefit from the newly laid out goals may find putting investment capital in companies focused on recycling, production, or materials procurement may be beneficial as the focus continues to gain momentum and support from Washington. 

 

Suggested Reading:

Can Mining be Green and Sustainable?

Inflation’s Impact on Stocks – Four Scenarios



Why Uranium Prices Have Been Rising

Who Benefits from the American Jobs Plan?

 

 

National
BluePrint for Lithium Batteries 2021-2030

 

Stay up to date. Follow us:

           


Stay up to date. Follow us:

Sierra Metals Announces Receipt Of Permit Allowing For A 20% Increase Of Throughput To 3,600 Tonnes Per Day At Its Yauricocha Mine In Peru

Posted on by Admin


Sierra Metals Announces Receipt Of Permit Allowing For A 20% Increase Of Throughput To 3,600 Tonnes Per Day At Its Yauricocha Mine In Peru

 

TORONTO–(BUSINESS WIRE)– Sierra Metals Inc. (TSX: SMT) (BVL: SMT) (NYSE AMERICAN: SMTS) (“Sierra Metals” or the “Company”) is pleased to announce the receipt of an Informe Técnico Minero (“ITM”) Permit from the Peruvian Ministry of Energy and Mines. The ITM Permit allows for the construction and operation at a capacity of 3,600 tonnes per day (“TPD”), at the Yauricocha Mine in Peru.

Luis Marchese, CEO of Sierra Metals commented: “I am delighted with the receipt of the ITM permit. The Company may now increase throughput at Yauricocha to 3,600 TPD which represents a 20% increase in throughput. Today’s news will further support the Company in achieving its annual production guidance.

Additionally, we continue focusing on the completion of the Prefeasibility Study at Yauricocha, which examines increasing throughput to 5,500 TPD starting in 2024, as well as on the Prefeasibility Studies for our Mexican operations.”

He concluded: “2021 continues to be an exciting year for the Company as we continue with organic growth plans including significant brownfield and greenfield exploration programs to support future mineral resource and production growth. Management also continues to focus on improving and modernizing our mine operations, increasing operating efficiencies to improve productivity and reduce costs.”

About Sierra Metals

Sierra Metals is a diversified Canadian mining company focused on the production and development of precious and base metals from its polymetallic Yauricocha Mine in Peru, and Bolivar and Cusi Mines in Mexico. The Company is focused on increasing production volume and growing mineral resources. Sierra Metals has recently had several new key discoveries and still has many more exciting brownfield exploration opportunities at all three Mines in Peru and Mexico that are within close proximity to the existing mines. Additionally, the Company also has large land packages at all three mines with several prospective regional targets providing longer-term exploration upside and mineral resource growth potential.

The Company’s common shares trade on the Toronto Stock Exchange and the Bolsa de Valores de Lima under the symbol “SMT” and on the NYSE American Exchange under the symbol “SMTS”.

Continue to Follow, Like and Watch our progress:

Web: www.sierrametals.com | Twitter: sierrametals | Facebook: SierraMetalsInc | LinkedIn: Sierra Metals Inc | Instagram: sierrametals

Forward-Looking Statements

This press release contains “forward-looking information” and “forward-looking statements” within the meaning of Canadian and U.S. securities laws related to the Company (collectively, “forward-looking information”). Forward-looking information includes, but is not limited to, statements with respect to the Company’s operations, including anticipated developments in the Company’s operations in future periods, the Company’s planned exploration activities, the adequacy of the Company’s financial resources, and other events or conditions that may occur in the future. Statements concerning mineral reserve and resource estimates may also be considered to constitute forward-looking statements to the extent that they involve estimates of the mineralization that will be encountered if and when the properties are developed or further developed. These statements relate to analyses and other information that are based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as “expects”, “anticipates”, “plans”, “projects”, “estimates”, “assumes”, “intends”, “strategy”, “goals”, “objectives”, “potential” or variations thereof, or stating that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative of any of these terms and similar expressions) are not statements of historical fact and may be forward-looking information.

Forward-looking information is subject to a variety of risks and uncertainties, which could cause actual events or results to differ from those reflected in the forward-looking information, including, without limitation, the risks described under the heading “Risk Factors” in our Annual Information Form dated March 30, 2021 in respect of the year ended December 31, 2020 and other risks identified in the Company’s filings with Canadian securities regulators and the U.S. Securities and Exchange Commission, which filings are available at www.sedar.com and www.sec.gov, respectively.

The risk factors referred to above is not exhaustive of the factors that may affect any of the Company’s forward-looking information. Forward looking information includes statements about the future and are inherently uncertain, and the Company’s actual achievements or other future events or conditions may differ materially from those reflected in the forward-looking information due to a variety of risks, uncertainties and other factors. The Company’s statements containing forward-looking information are based on the beliefs, expectations and opinions of management on the date the statements are made, and the Company does not assume any obligation to update forward-looking information if circumstances or management’s beliefs, expectations or opinions should change, other than as required by applicable law. For the reasons set forth above, one should not place undue reliance on forward-looking information.

For further information regarding Sierra Metals, please visit www.sierrametals.com or contact:

Mike McAllister
V.P., Investor Relations
Sierra Metals Inc.
+1 (416) 366-7777
Email: info@sierrametals.com

Luis Marchese
CEO
Sierra Metals Inc.
+1(416) 366-7777

Source: Sierra Metals Inc.

China Fighting Cost Push Inflation with Metals Reserves

Posted on by Admin


Why are the Chinese Releasing Copper, Aluminum, and Zinc Reserves?

 

When the U.S. Federal Reserve looks to curb producer price inflation, they may take money out of the economy to impact the demand side of the equation. When China is looking to squelch its factory gate inflation, they grow the supply side by releasing reserves of raw materials. At least that is what they announced today (6/16) related to some base metals. 

China is the world’s top metals consumer. A spike in inflation of Chinese made goods would reduce the countries global competitive position. This could lead to decreased exports. For this reason, it’s in the countries best interest to cool the roaring price increases of copper, aluminum, zinc, and others. Prices have been surging this year in reaction to post-pandemic spikes in demand and some speculative buying around the commodities. With today’s announcement, speculators are warned that buying may lead to unintended “pain.” This alone helps to tame prices at the producer or factory stage. 

 

Background/ What is Impacted

Chinese factory gate inflation is the rough equivalent to the U.S. Bureau of Labor Statistics measure of producer price inflation. Factory gate prices jumped to the highest level in over 12 years during May. The higher costs cut into profit margins of final product producers because much of the cost was not able to be passed on to consumers. Global price pressures have been on the rise in many countries as policymakers have been working to revitalize post-Covid-19 economies without unwanted inflation. The balance needed to achieve both has been a growing challenge.

Prices on copper contracts on the Shanghai Futures Exchange and the London Metal Exchange hit record highs in May, after having risen more than 60% since March 2020 as the reaction to the pandemic began to affect global markets. On their website, the Chinese National Food and Strategic Reserves Administration said that it will release reserves for public bid including copper, aluminum, and zinc in batches for nonferrous processing and manufacturing. The sales are not completely unexpected by metals traders as Chinese regulators have been stepping up efforts to cool commodity prices in recent weeks.

 

Take-Away

The Chinese authorities are trying to help support the margins of its manufacturing industry as passing along manufacturing costs to end consumers have not been overly successful. This bodes well for the argument that recent spikes in inflation may be temporary and related to spikes in demand that will level out over time. The Chinese National Food and Strategic Reserves Administration is doing its part to add supplies at a time when demand and speculation of increased demand is at an abnormal peak. The move may help to calm the volatility we have seen in other parts of the world in commodity prices.

Today the Federal Open Market Committee (FOMC) will end their two-day June meeting where U.S. inflation is on their agenda as well. The world markets await being updated on the Fed’s plans for scaling back what are seen as inflationary monetary policies. The Fed statement post meeting typically is made public at 2 pm following the FOMC’s adjournment.

 

Suggested Reading:

The PCE Deflator and the Trimmed PCE Inflation Rate Tell Different Stories

Will Mortgage Forbearance Impact Other Markets?



How Much is a Trillion?

Bond Market Understanding is Now Critical for Stock Investors

 

Virtual Road Show Series – Thursday, Jun 17, @ 1pm EDT

Join Chakana Copper CEO David Kelley for this exclusive corporate presentation, followed by a Q & A session moderated by Mark Reichman, Noble’s senior research analyst, featuring questions taken from the audience. Registration is free and open to all investors, at any level.

Register Now  |  View All Upcoming Road Shows

 

Sources:

https://www.wsj.com/articles/china-to-release-metal-reserves-in-effort-to-tame-commodities-rally-11623825424?mod=searchresults_pos3&page=1

https://www.wsj.com/articles/copper-falls-to-eight-week-low-on-fear-china-might-release-stockpiles-11623761899?mod=searchresults_pos5&page=1

 

Stay up to date. Follow us:

           


Stay up to date. Follow us:

Kratos Named One of the First Cybersecurity Maturity Model Certification (CMMC) Third Party Assessment Organizations (C3PAO)

Posted on by Admin


Kratos Named One of the First Cybersecurity Maturity Model Certification (CMMC) Third Party Assessment Organizations (C3PAO)

 

SAN DIEGO, 
June 15, 2021 (GLOBE NEWSWIRE) — 
Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a leading National Security Solutions provider, announced today that it has been named by the federal government as one of the first two CMMC Third Party Assessment Organizations (C3PAO). As a C3PAO, Kratos will be able to conduct CMMC Level 1-3 assessments once the government completes certain preparatory and authorization steps.

The CMMC is a new unified security standard and a certification process developed by the 
U.S. Department of Defense (
DoD) to protect the security of Federal Contract Information (FCI) and Controlled Unclassified Information (CUI) within the Defense Industrial Base (DIB). In accordance with recent updates to DFARS 252.204, the 
Office of the Under Secretary of Defense (OUSD) will begin a phased rollout requiring contractors to achieve CMMC certification. Once the rollout is complete, nearly all companies seeking to respond to 
DoD proposal requests will require CMMC certification.

Kratos has years of robust experience in compliance and certification, risk management and cyber operations, defense and engineering. Services include vulnerability assessments, enterprise security architecture design, application security testing and risk management processes. Kratos cybersecurity services support the development and operation of proactive cybersecurity programs, the development of enterprise cloud security strategies, and the establishment of sound and practical information security architectures tailored to organizational needs.

Mark Williams, Vice President, Kratos Cybersecurity Services explained: “As a member of the DIB Kratos underwent a rigorous assessment by the Defense Industrial Base Cybersecurity Assessment Center, which was a key factor in its early C3PAO authorization by the 
CMMC AB.” Once authorized to begin conducting assessments. Kratos’ Provisional Assessor-led teams will conduct the CMMC assessments that consist of up to four phases. The Planning phase includes assessment plan development and an assessment readiness review. The Assessment phase includes collecting and validating the required Objective Evidence (OE) and generating final results. Presentation of the results occurs in the Report Findings phase. If issues are identified in the Report Findings phase, the Remediation phase is dedicated to evaluating remedial actions taken. Depending on the assessment complexity Kratos estimates that most assessments will be completed in four to six weeks.

Phil Carrai, President of Kratos Space, Training and Cyber Division highlighted the importance of a robust CMMC program. “The recent spate of data breaches affecting both government and commercial organizations underscores the need for more robust security measures to protect critical information. For 
DoD this means increased protection of FCI and CUI data. CMMC will be a critical component of heightened security as all companies will need to pass strict CMMC security assessments before being awarded 
DoD contracts. Kratos is proud to be named one of the first C3PAOs. Our extensive experience in providing advisory and assessment services for compliance frameworks such as FedRAMP and others position us well to support CMMC.”

For more information on Kratos’ CMMC services visit: https://www.kratosdefense.com/cmmc-c3pao.

About Kratos Defense & Security Solutions

Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) develops and fields transformative, affordable technology, platforms and systems for United States National Security related customers, allies and commercial enterprises. Kratos is changing the way breakthrough technology for these industries are rapidly brought to market through proven commercial and venture capital backed approaches, including proactive research and streamlined development processes. Kratos specializes in unmanned systems, satellite communications, cyber security/warfare, microwave electronics, missile defense, hypersonic systems, training, combat systems and next generation turbo jet and turbo fan engine development. For more information go to www.KratosDefense.com.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended 
December 27, 2020, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the 
SEC by Kratos.

Press Contact:
Yolanda White
858-812-7302 Direct

Investor Information:
877-934-4687
investor@kratosdefense.com

Source: Kratos Defense & Security Solutions, Inc.

Lineage Cell Therapeutics Announces Kevin L. Cook To Join As Chief Financial Officer

Posted on by Admin


Lineage Cell Therapeutics Announces Kevin L. Cook To Join As Chief Financial Officer

 

CARLSBAD, Calif.–(BUSINESS WIRE)–Jun. 16, 2021– 

Lineage Cell Therapeutics, Inc.
 (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that  Kevin Cook will join as the Company’s Chief Financial Officer, effective 
June 21, 2021.  Mr. Cook will bring more than 20 years of significant strategic, financial, and operational experience to Lineage, with an emphasis in private equity, corporate finance, and investment banking.  Mr. Cook has broad expertise across a range of financial matters and has executed over 
$30 billion of capital raising and corporate development transactions, approximately half of which involved life sciences companies.

“We are excited to welcome Kevin to Lineage as we continue our journey to become a leading cell therapy and cell transplant company,” stated  Brian M. Culley, Lineage CEO. “Kevin is a talented and skilled executive with a proven track record of execution across an array of strategic and financial disciplines. We believe he will be an important addition to the Lineage team and his breadth of experience will contribute significantly to our future success as we advance our product candidates into later stage clinical trials and seek to align strategically with financial and developmental partners to support our further growth.”

Mr. Cook most recently served as Chief Operating Officer of a family office investment firm with an emphasis in the solar energy and infrastructure industries, where he managed existing portfolio companies while pursuing new control investments. From 2012 to 2019, he served as Vice President of Corporate Development and Strategy and Vice President of Business Development for 
Breitburn GP LLC, where he led aggressive growth and diversification efforts for 
Breitburn Energy and affiliates. From 2000 to 2011,  Mr. Cook served as an investment banker for Merrill Lynch & Co., where he advised life sciences companies and other clients across a range of industries in connection with corporate finance and strategic assignments.  Mr. Cook earned his M.B.A. from Northwestern University’s 
Kellogg Graduate School of Management and his B.S. from the 
University of California, Davis.

About Lineage Cell Therapeutics, Inc. 

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic dendritic cell therapy produced from Lineage’s VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.

Forward-Looking Statements

Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “can,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” project,” “target,” “tend to,” or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to Mr. Cook’s employment with Lineage and appointment as CFO and the anticipated impact thereof, clinical development of Lineage’s product candidates, and Lineage’s anticipated growth and potential partnerships in furtherance thereof. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineage’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including risks and uncertainties inherent in Lineage’s business and other risks in Lineage’s filings with the 
Securities and Exchange Commission (SEC). Lineage’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading “Risk Factors” in Lineage’s periodic reports with the 
SEC, including Lineage’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the 
SEC and its other reports, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
(ir@lineagecell.com)
(442) 287-8963

Solebury Trout IR
Gitanjali Jain Ogawa
(Gogawa@soleburytrout.com)
(646) 378-2949

Russo Partners – Media Relations
Nic Johnson or  David Schull
Nic.johnson@russopartnersllc.com
David.schull@russopartnersllc.com
(212) 845-4242

Source: 
Lineage Cell Therapeutics, Inc.

Release – Helius Medical Technologies Expands Executive Leadership Team

Posted on by Admin


Helius Medical Technologies, Inc. Expands Executive Leadership Team with the Appointment of Dane C. Andreeff as President and Chief Executive Officer and Jeffrey S. Mathiesen as Chief Financial Officer

 

NEWTOWN, Pa., June 15, 2021 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that Dane C. Andreeff and Jeffrey S. Mathiesen have been appointed to the respective positions of President and Chief Executive Officer and Chief Financial Officer, effective June 14, 2021. Joyce LaViscount will continue to serve as the Company’s Chief Operating Officer.

Mr. Andreeff has served as Helius’ Interim President and Chief Executive Officer since August 2020 and as a member of the Company’s Board of Directors since August 2017. Mr. Mathiesen served as a member of Helius’ Board of Directors and Chair of the Company’s Audit Committee from June 2020 to June 2021.

“After significant evaluation and deliberation, my fellow board members and I are very pleased to announce the appointment of Dane and Jeff to the executive leadership team,” said Blane Walter, Chairman of the Board of Directors of Helius. “Dane and Jeff possess an important combination of strong leadership skills and extensive experience in managing companies and guiding their strategic development, making them ideal candidates to lead Helius as we enter the next stage of growth and development as an organization.”

Mr. Walter continued: “In addition to these qualities, Dane and Jeff are highly skilled financial executives with more than 20 years of senior-level financial leadership experience, are well-versed in our business and its strategic priorities, and have demonstrated their strategic expertise and insight through their prior roles at Helius. We look forward to their future contributions as members of our executive leadership team.”

“As a strong believer in both the PoNSTM technology and its ability to improve the lives of patients, as well as the capabilities and commitment of our organization to facilitating its availability and adoption, I am excited to assume the role of President and Chief Executive Officer,” said Mr. Andreeff. “Looking ahead, I remain committed to building upon the recent progress made during the last year, and delivering strong, strategic and operational execution for the benefit of patients, providers, payors, and shareholders.”

“It is a great pleasure to join the Helius executive leadership team at such an exciting and important point in the Company’s history,” said Mr. Mathiesen. “I look forward to contributing to Helius’ success as we position the Company for growth during this crucial next phase.”

About Dane C. Andreeff

Mr. Andreeff served as Interim President and Chief Executive Officer of Helius since August 2020, and serves as the General Partner and Portfolio Manager at Maple Leaf Partners, LP, which owns approximately 5% of Helius’ outstanding Class A common stock. Maple Leaf Partners, LP is a hedge fund founded by Mr. Andreeff, where he has been employed since 1996. In 2003, the fund was seeded by Julian Robertson’s Tiger Management and later grew to over $2 billion in assets under management.

Mr. Andreeff has served as a member of the Board of Directors of HDL Therapeutics, Inc., a privately held medical technology and device company focused on infusing plasma with pre?-HDL for the treatment of multiple cardiovascular indications, since 2012, and Myocardial Solutions, Ltd., a privately held medical technology company with an FDA-cleared cardiac MRI software known as MyoStrain® that provides a 10-minute test for detecting heart dysfunction in multiple cardiovascular indications – including cardiotoxicity in cancer treatment, since 2016.

Mr. Andreeff received his Bachelor’s degree in Economics from the University of Texas at Arlington in 1989 and his Master’s degree in Economics from the University of Texas at Arlington in 1991.

About Jeffrey S. Mathiesen, CPA

Mr. Mathiesen has nearly 30 years of experience as Chief Financial Officer of growth oriented, technology-based companies across a wide range of industries including biopharmaceutical and medical device companies. His experience includes three initial public offerings on Nasdaq, new product launches and multiple M&A transactions. Mr. Mathiesen previously served as Chief Financial Officer of Gemphire Therapeutics Inc., a publicly traded, clinical-stage biopharmaceutical company, and as Chief Financial Officer of Sunshine Heart, Inc., a publicly traded, early-stage medical device company.

Mr. Mathiesen currently serves as Director and Audit Committee Chair of NeuroOne Medical Technologies Corporation, a publicly-traded medical technology company providing neuromodulation continuous EEG monitoring and treatment solutions for patients suffering from epilepsy and other nerve related disorders, and as Lead Independent Director and Audit Committee Chair of Panbela Therapeutics, Inc., a publicly-traded, clinical-stage biopharmaceutical company developing therapies for pancreatic diseases.

Mr. Mathiesen began his career at Deloitte & Touche LLP in 1983. He received a B.S. in Accounting from the University of South Dakota and is also a Certified Public Accountant.

About Helius Medical Technologies, Inc.

Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNSTM). For more information, visit www.heliusmedical.com.

About the PoNS™ Device and PoNS Treatment™

The Portable Neuromodulation Stimulator (PoNSTM) is an innovative non-surgical device, inclusive of a controller and mouthpiece, which delivers electrical stimulation to the surface of the tongue to provide treatment of gait deficit. The PoNS device is indicated for use in the United States as a short term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis (“MS”) and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only. It is authorized for sale in Canada as a class II, non-implantable, medical device intended as a short term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS, and chronic balance deficit due to mild-to-moderate traumatic brain injury (“mmTBI”) and is to be used in conjunction with physical therapy. PoNS is an investigational medical device in the European Union (“EU”) and Australia (“AUS”). It is currently under premarket review by the AUS Therapeutic Goods Administration.

Investor Relations Contact:

Westwicke on behalf of Helius Medical Technologies, Inc.
Jack Powell, Vice President
investorrelations@heliusmedical.com

Cautionary Disclaimer Statement: 

Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by terms such as “believe,” “continue,” “looking ahead,” “will,” “committed to,” “goal,” “expect,” “remain,” “hope” and similar expressions. Such forward-looking statements include, among others, statements regarding the Company’s future strategic and operational execution, the next phase of the Company’s market development activities, clinical and regulatory development plans for the PoNS device, and the timing and success of the Company’s commercialization efforts in the United States.

These statements involve substantial known and unknown risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied by such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include uncertainties regarding the Company’s capital requirements to achieve its business objectives, the impact of the COVID-19 pandemic, the Company’s ability to train physical therapists in the supervision of the use of the PoNS Treatment, the Company’s ability to secure contracts with rehabilitation clinics, the Company’s ability to obtain national Medicare coverage and to obtain a reimbursement code so that the PoNS device is covered by Medicare and Medicaid, the Company’s ability to build internal commercial infrastructure, market awareness of the PoNS device, future clinical trials and the clinical development process, manufacturing and supply chain risks, potential changes to the MCIT program, the product development process and FDA regulatory submission review and approval process, other development activities, ongoing government regulation, and other risks detailed from time to time in the “Risk Factors” sections of the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, its Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 and its other filings with the United States Securities and Exchange Commission and the Canadian securities regulators, which can be obtained from either at www.sec.gov or www.sedar.com.The reader is cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law.

The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Voyager Digital Ltd. (VYGVF)(VYGR:CA) – Initiation on Voyager Digital: the Fastest Growing Digital Asset Broker

Posted on by Admin

Tuesday, June 15, 2021

Voyager Digital Ltd. (VYGVF)(VYGR:CA)
Initiation on Voyager Digital: the Fastest Growing Digital Asset Broker

Voyager Digital Ltd through its subsidiary, operates as a crypto asset broker that provides retail and institutional investors with a turnkey solution to trade crypto assets. The company offers investors execution, data, wallet and custody services through its institutional-grade open architecture platform.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Kevin Wahle, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Initiating Coverage. We are initiating research coverage on Voyager Digital Ltd. Voyager is a leading-edge, commission-free, crypto-currency brokerage. We believe the Company is well positioned to capitalize on fast growing interest in the cryptocurrency space, whiling leveraging its platform to become the central financial platform for its clients.

    Leading Crypto Trading Platform With Stickiness.  Voyager’s platform enables trading on over 60 (and growing) different cryptocurrencies and assets, the largest of any platform. In addition, the Company pays interest on 20 of the coins, providing a reason for clients to move assets to, and keep them on, the platform. Voyager provides faster execution and deeper liquidity, often enabling clients to …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Release – PDS Biotech Prices Public Offering of Common Stock

Posted on by Admin


PDS Biotech Prices Public Offering of Common Stock

 

FLORHAM PARK, N.J., June 14, 2021 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced the pricing of its previously announced underwritten public offering of 5,294,118 shares of its common stock at a public offering price of $8.50 per share. The gross proceeds to PDS Biotech, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $45.0 million. All of the shares of common stock to be sold in the offering are being offered by PDS Biotech. PDS Biotech has granted the underwriters a 30-day option to purchase up to an additional 794,117 shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about June 17, 2021, subject to customary closing conditions.

Cantor Fitzgerald & Co. is acting as sole bookrunner for the offering.

PDS Biotech intends to use a portion of the net proceeds from this offering for the development of our clinical pipeline and for general corporate purposes including working capital.

A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (the “SEC”) and became effective on July 31, 2020. A preliminary prospectus supplement relating to the offering has been filed with the SEC. Copies of the preliminary prospectus supplement and accompanying prospectus may be obtained from Cantor Fitzgerald & Co., 499 Park Avenue, 4th Floor, New York, NY 10022, Attn: Capital Markets Department, or by email at prospectus@cantor.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of cancer immunotherapies based on the Company’s proprietary Versamune® T-cell activating technology platform. Our Versamune®-based products overcome the limitations of current immunotherapy by inducing in vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells. PDS Biotech has developed multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them. Our immuno-oncology product candidates are initially being studied in combination therapy to potentially enhance efficacy without compounding toxicity across a range of cancer types. The Company’s lead investigational cancer immunotherapy product PDS0101 is currently in Phase 2 clinical studies in HPV-associated cancers. The Company’s pipeline products address various cancers including breast, colon, lung, prostate and ovarian cancers.

Forward Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotech and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to complete the contemplated offering; the Company’s anticipated capital requirements; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company’s annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Media & Investor Relations Contact:

Deanne Randolph
PDS Biotech
Phone: +1 (908) 517-3613
Email: drandolph@pdsbiotech.com

Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
Email: rich@cg.capital

Release – PDS Biotech Announces Proposed Offering of Common Stock

Posted on by Admin


PDS Biotech Announces Proposed Offering of Common Stock

 

FLORHAM PARK, N.J., June 14, 2021 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares of common stock to be sold in the offering will be offered by PDS Biotech. PDS Biotech intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Cantor Fitzgerald & Co. is acting as sole bookrunner for the offering.

PDS Biotech intends to use a portion of the net proceeds from this offering for the development of our clinical pipeline and for general corporate purposes including working capital.

A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (the “SEC”) and became effective on July 31, 2020. A preliminary prospectus supplement relating to the offering has been filed with the SEC. Copies of the preliminary prospectus supplement and accompanying prospectus may be obtained from Cantor Fitzgerald & Co., 499 Park Avenue, 4th Floor, New York, NY 10022, Attn: Capital Markets Department, or by email at prospectus@cantor.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of cancer immunotherapies based on the Company’s proprietary Versamune® T-cell activating technology platform. Our Versamune®-based products overcome the limitations of current immunotherapy by inducing in vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells. PDS Biotech has developed multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them. Our immuno-oncology product candidates are initially being studied in combination therapy to potentially enhance efficacy without compounding toxicity across a range of cancer types. The Company’s lead investigational cancer immunotherapy product PDS0101 is currently in Phase 2 clinical studies in HPV-associated cancers. The Company’s pipeline products address various cancers including breast, colon, lung, prostate and ovarian cancers.

Forward Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotech and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to complete the contemplated offering; the Company’s anticipated capital requirements; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company’s annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Media & Investor Relations Contact:

Deanne Randolph
PDS Biotech
Phone: +1 (908) 517-3613
Email: drandolph@pdsbiotech.com

Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
Email: rich@cg.capital

Comtech (CMTL) – Outerbridge Seeks Strategic Alternatives

Posted on by Admin

Tuesday, June 15, 2021

Comtech (CMTL)
Outerbridge Seeks Strategic Alternatives

Comtech Telecommunications Corp. engages in the design, development, production, and marketing of products, systems, and services for advanced communications solutions in the United States and internationally. It operates in three segments: Telecommunications Transmission, Mobile Data Communications, and RF Microwave Amplifiers. The Telecommunications Transmission segment provides satellite earth station equipment and systems, over-the-horizon microwave systems, and forward error correction technology, which are used in various commercial and government applications, including backhaul of wireless and cellular traffic, broadcasting (including HDTV), IP-based communications traffic, long distance telephony, and secure defense applications. The Mobile Data Communications segment provides mobile satellite transceivers, and computers and satellite earth station network gateways and associated installation, training, and maintenance services; supplies and operates satellite packet data networks, including arranging and providing satellite capacity; and offers microsatellites and related components. The RF Microwave Amplifiers segment designs, develops, manufactures, and markets satellite earth station traveling wave tube amplifiers (TWTA) and broadband amplifiers. Its amplifiers are used in broadcast and broadband satellite communication; defense applications, such as telecommunications systems and electronic warfare systems; and commercial applications comprising oncology treatment systems, as well as to amplify signals carrying voice, video, or data for air-to-satellite-to-ground communications. The company serves satellite systems integrators, wireless and other communication service providers, broadcasters, defense contractors, military, governments, and oil companies. Comtech markets its products through independent representatives and value-added resellers. The company was founded in 1967 and is headquartered in Melville, New York.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Kevin Wahle, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Outerbridge Letter. Yesterday, Outerbridge Capital announced it had delivered a letter to Comtech’s BoDs seeking a review of strategic alternatives. According to the letter, while Outerbridge believes “Comtech continues to be a market leader with best-in-class products and strong growth prospects, the Company…remains significantly undervalued.” Outerbridge values CMTL shares in the $32-$40 range.

    Who Is Outerbridge? Founded by Rory Wallace, Outerbridge is a New York-based investment adviser that typically invests across the technology and technology-impacted sectors.  Probably its most well known play was at Barnes & Noble Education, where Outerbridge also pushed for a strategic review. Ultimately, the investment advisor ended up with two Board seats …



This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

QuickChek – June 15, 2021

Posted on by Admin



PDS Biotech Announces Proposed Offering of Common Stock

– commenced an underwritten public offering of shares of its common stock
– announced the pricing of its underwritten public offering

Research, News & Market Data on PDS Biotechnology

Watch recent presentation from PDS Biotech



Lineage Cell Therapeutics To Present At Raymond James 2021 Human Health Innovation Conference On June 22, 2021

Lineage Cell Therapeutics announced that CEO Brian M. Culley will be presenting at the Raymond James 2021 Human Health Innovation Conference

Research, News & Market Data on Lineage Cell Therapeutics

Watch recent presentation from Lineage Cell



Ocugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™

Ocugen, Inc. announced that it has selected Jubilant HollisterStier of Spokane, Washington as its manufacturing partner for COVAXIN™ to prepare for potential commercial manufacturing of COVAXIN™ for the US and Canadian markets.

News & Market Data on Ocugen

Watch recent presentation from Ocugen



Aurania Reports That Drilling Has Intersected Sediment-Hosted Copper Mineralization At Tsenken N1

Aurania Resources reported that drilling has intersected sediment-hosted copper mineralization at Tsenken N1 in the Company’s Lost Cities – Cutucu Project in southeastern Ecuador

Research, News & Market Data on Aurania Resources

Watch recent presentation from NobleCon17



Namaste Technologies Provides Corporate Update

Namaste Technologies announced that it is presently receiving a record amount of requests from vendors across North America to list their products onto the CannMart.com platform

Research, News & Market Data on Namaste Technologies

Watch recent presentation from NobleCon17



Helius Medical Technologies, Inc. Expands Executive Leadership Team

Helius Medical Technologies announced it has appointed Dane C. Andreeff as President and CEO and Jeffrey S. Mathiesen as CFO

Research, News & Market Data on Helius Medical

Watch recent presentation from Helius

Stay up to date. Follow us:

Release – Lineage Cell Therapeutics To Present At Raymond James 2021 Human Health Innovation Conference On June 22 2021

Posted on by Admin


Lineage Cell Therapeutics To Present At Raymond James 2021 Human Health Innovation Conference On June 22, 2021

 

CARLSBAD, Calif.–(BUSINESS WIRE)–Jun. 15, 2021– 

Lineage Cell Therapeutics, Inc.
 (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that  Brian M. Culley, Chief Executive Officer, will be presenting at the Raymond James 2021 
Human Health Innovation Conference being held virtually on 
June 22, 2021 at 
1:20 p.m. Eastern Time / 
10:20 a.m. Pacific Time. Interested investors can access the live and archived webcasts on the Events and Presentations section of Lineage’s website. Additional videos are available on the Media page of the Lineage website.

About Lineage Cell Therapeutics, Inc. 

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic dendritic cell therapy produced from Lineage’s VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.

Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
(ir@lineagecell.com)
(442) 287-8963

Solebury Trout IR
Gitanjali Jain Ogawa
(Gogawa@soleburytrout.com)
(646) 378-2949

Russo Partners – Media Relations
Nic Johnson or  David Schull
Nic.johnson@russopartnersllc.com
David.schull@russopartnersllc.com
(212) 845-4242

Source: 
Lineage Cell Therapeutics, Inc.

Release – Namaste Technologies Provides Corporate Update

Posted on by Admin


Namaste Technologies Provides Corporate Update

 

TORONTO, June 15, 2021 (GLOBE NEWSWIRE) — Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV: N) (FRANKFURT: M5BQ) (OTCMKTS: NXTTF) a marketplace platform for cannabis and wellness products, is pleased to provide the following corporate updates:

550+ New SKUs on CannMart.com

Namaste is very excited to announce that it is presently receiving a record amount of requests from vendors across North America to list their products onto the CannMart.com platform. This validation is a clear statement from an increasing amount of vendors that the CannMart.com marketplace platform can make a valuable differentiated distribution channel which has resulted in over 550 SKUs launched in the last three months including items from these popular brands:

In Canada we have launched SKUs from the following brands:

  • Bello Vapor Tap – The world’s first vapor tap
  • Emprise – A wide range of proprietary water-soluble nano-emulsion oils and sprays
  • Heritage Cannabis – Industry leader in cannabinoid extractions and CPG innovations
  • Kalaya – Medically directed, health and beauty care brand that uses problem-solution based formulations
  • KUSHKRAFT – Embracing the rich history of cannabis by integrating its vast culture into the licensed market
  • Lumiera Health – AwayeTM – A non-regulated cannabinoid derived topical cream for the potential treatment of joint and muscle pain

In the USA we have further expanded our platform with the addition of SKUs from the following brands:

  • 7NRG – World’s first fully recyclable sports nutrition shake that combines energy and protein powders with hemp derived CBD
  • CBD For The People – A hemp derived CBD flower producer
  • Martha Stewart CBD – Combining gourmet flavors with state-of-the-art hemp derived CBD isolate
  • Kine Industries – Sublingual products infused with the highest quality hemp derived CBD and CBG extracted from industrial hemp that contain no THC, and are vegan and gluten free
  • FullBodyZen – a vertically integrated hemp derived CBD / CBG / Hemp / Melatonin Supplier
  • Shine Brands – Parent company of Shine Papers is the inventor of the world’s first 24K gold rolling paper

Namaste Corporate Makes Move to Virtual Office Permanent:

The Company has successfully subleased its Toronto office location until expiry of its lease on October 30, 2024 such that all corporate staff now work virtually from anywhere in the world.

“We are a global company that hires the best talent irrespective of their location,” said Meni Morim, CEO of Namaste. “Furthermore, we are committed to reducing our carbon footprint as part of developing Environmental, Social and Governance (ESG) plans, appreciating that ESG is increasing in importance to all stakeholders.”

This strategic and sustainable decision will also save the Company approximately $138,000 annually.

Award Grants:

The Board of Directors and its compensation committee consulted with independent industry experts to best determine the overall remuneration package to stay competitive in the marketplace and to attract and retain top-tier talent. Long term incentive program benchmarks, including option and RSU grants, were established from peer companies with comparable market capitalization, operating not only within the cannabis sector, but in similar and adjacent sectors, and compared against historical grants and standards. Long term incentives that vest over multiple years tie individual success with the long-term success of the Company without impacting cash resources.

To that end, the Board of Directors yesterday approved, effective after market close, the grant of an aggregate of 311,250 stock options to officers and a consultant of the Company, which are exercisable into common shares of Namaste at a price of $0.25 per common share, having previously granted on May 6, 2021, 735,800 stock options to non-officer employees and a consultant of the Company, in accordance with the rules of the TSX Venture Exchange and the Company’s Stock Option Plan. The stock options granted to officers and employees have a term of four years in equal tranches every six months over three years from the applicable grant date and will expire on June 13, 2025 and May 5, 2025 respectively.

In addition, at the same time, the Board of Directors approved the grant of 311,250 restricted share unit awards (“RSUs”) in favour of officers and a consultant of the Company thereby reserving 311,250 commons shares for issuance in connection therewith, having previously granted on May 6, 2021, 535,800 RSUs in favour of non-officer employees in the Company, all in accordance with the rules of the TSX Venture Exchange and the Company’s Restricted Share Unit Plan adopted by the shareholders at the Company’s last AGM. The RSUs granted to officers and employees vest in equal tranches every six months over three years from the date of their respective grants.

For further information on Namaste’s public disclosure, consult the Company’s issuer profile on SEDAR at www.sedar.com.

About Namaste Technologies Inc.
Namaste Technologies is a marketplace platform for cannabis and wellness products. At CannMart.com, the Company provides Canadian medical customers with a diverse selection of hand-picked products from a multitude of federally licensed cultivators and US customers with access to hemp-derived CBD and smoking accessories. The Company also distributes licensed and in-house branded cannabis and cannabis derived products in Canada through a number of provincial government control boards and retailing bodies and facilitates licensed cannabis retailer sales online in Saskatchewan. Namaste’s global technology and continuous innovation address local needs in a burgeoning cannabis industry requiring smart solutions.

Information on the Company and its many products can be accessed through the links below:

NamasteTechnologies.com

NamasteMD.com

Cannmart.com

For more information please contact:
Namaste Technologies Inc.
Meni Morim, CEO
Edward Miller, VP Investor Relations
Ph: 647-362-0390
Email: ir@namastetechnologies.com

Source: Namaste Technologies Inc

FORWARD-LOOKING INFORMATION – This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not historical in nature contain forward-looking information. Forward-looking information can be identified by words or phrases such as “may”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen.

The forward-looking information contained herein, are made as of the date of this press release and are based on assumptions management believed to be reasonable at the time such statements were made. While we consider these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct. By its nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this press release. Such factors include, without limitation: the Company’s ability to successfully operate everywhere in a virtual environment. Additional risk factors can also be found in the Company’s current MD&A and annual information form, both of which have been filed under the Company’s SEDAR profile at www.sedar.com. Readers are cautioned not to put undue reliance on forward-looking information. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release or has in any way approved or disapproved of the contents of this press release.

Source: Namaste Technologies Inc.